DRAFT NICE guidance issued in May 2014 did not recommend abiraterone for prostate cancer which has spread in men whose first treatment has failed, have no or mild symptoms and for whom chemotherapy is not yet clinically indicated. However, the drug is available for this indication via the Cancer Drugs Fund.